Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

Inclusion Criteria: * Adult subject and pediatric subjects (aged greater than or equal to two (2) years). * Is referred for a contrast-enhanced MRI of the CNS based on the results of a previous imaging procedure. * Female of childbearing potential patients must have effective contraception (contraceptive pill or intra-uterine device) or be surgically sterilized or post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI. * Has been fully informed about the study, and has consented to participate. Exclusion Criteria: * Having acute or chronic grade IV or V renal insufficiency. * Known class III/IV congestive heart failure. * Suffering from long QT syndrome. * Unstable health condition or circumstances (e.g. suffering from severe claustrophobia). * Having any contraindications to MRI such as a pace-maker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field. * Known allergy to Gadolinium chelates. * Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration. * Pregnant, breast feeding, or planning to become pregnant during the trial. * Previously participated in this trial. * Having participated within 30 days in another clinical trial involving an investigational drug. * Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits. * Inability or unwillingness to cooperate with the requirements of this trial.